查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970819

非注射胰岛素市场－全球产业规模、份额、趋势、机会、预测：按产品、通路、地区和竞争格局划分，2021-2031年

Non-Injectable Insulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球非注射胰岛素市场预计将从 2025 年的 36.9 亿美元成长到 2031 年的 64.6 亿美元，复合年增长率为 9.78%。

此市场领域专注于替代给药途径，例如肺部吸入和口服製剂，旨在无需使用侵入性针头即可给药。推动这一增长的主要因素是全球糖尿病患者人数的不断增加，以及提高患有针头恐惧症和注射疲劳患者的治疗依从性的迫切需求。根据国际糖尿病联盟的数据，到2025年，全球将有约5.89亿成年人患有糖尿病，如此庞大的患者群体推动了对便捷替代疗法的巨大需求，这些疗法能够克服与传统皮下注射相关的生理和心理障碍。

市场概览
预测期 2027-2031
市场规模：2025年 36.9亿美元
市场规模：2031年 64.6亿美元
复合年增长率：2026-2031年 9.78%
成长最快的细分市场 药局
最大的市场 北美洲

儘管非注射药物对患者生活品质的益处显而易见，但市场仍面临一个重大障碍：与标准注射药物相比，非注射药物的生物利用度较低。这种生理限制通常需要更高的剂量才能达到相同的治疗效果，从而显着增加生产成本，最终加重患者的负担。因此，严格的报销机制和与这些治疗相关的高昂经济负担成为市场成长的主要障碍，阻碍了成本敏感地区的临床应用。

市场驱动因素

非注射胰岛素产业的主要驱动力是全球糖尿病发生率的上升。这导致人们越来越需要提高患者的治疗顺从性，因为他们每天都要承受注射带来的心理和生理负担。疾病盛行率的上升推动了扩充性、易于使用且能缓解针头恐惧症的治疗方法的需求。国际糖尿病联盟 (IDF) 的《IDF 糖尿病地图集》（第 11 版）预测，到 2050 年，糖尿病成人患者人数将达到约 8.53 亿，这凸显了替代给药系统的重要性。这种需求的规模也反映在大型製药公司的业务规模上。例如，截至 2024 年，诺和诺德为超过 4,520 万名患有严重慢性疾病的患者提供服务，这表明等待非侵入性治疗方法的患者群体规模庞大。

同时，对替代胰岛素製剂研发投入的增加正在推动整个产业的发展。製药公司正积极投资吸入和口服给药系统的创新，以克服传统的生物利用度问题并提高治疗效果。这些资金投入对于引导新技术从临床试验走向商业化至关重要。一个显着的例子是，2025年2月，Oramed Pharmaceuticals宣布成立一家总额达7,500万美元的策略合资企业，旨在加速其口服胰岛素平台的开发和商业化。如此大规模的资金注入凸显了该行业对非侵入性解决方案的承诺，并有望透过实现无痛胰岛素给药，推动下一阶段的市场扩张。

市场挑战

全球非注射胰岛素市场成长面临的主要障碍之一是肺部给药和口服製剂的生物利用度低于标准注射製剂这一生理问题。由于这些替代给药途径难以有效穿过生物屏障，生产商必须配製含有更高浓度活性胰岛素的药物，以确保患者获得必要的治疗剂量。活性成分的增加直接推高了生产成本，导致最终价格显着上涨，从而限制了保险公司和患者的购买力。

这种价格差异在医疗预算本已捉襟见肘的地区构成了一大障碍。严格的报销政策往往优先考虑价格较低的传统注射药物，导致价格昂贵的非注射药物缺乏足够的健保覆盖。近期有关糖尿病经济影响的统计数据凸显了这种经济压力的规模。根据国际糖尿病联盟（IDF）预测，到2025年，全球糖尿病医疗费用支出将至少达到1兆美元。鑑于如此庞大的现有成本，支付方对引入高价疗法仍然持谨慎态度，导致这些疗法在临床实践中的普及程度有限，并阻碍了对成本敏感地区的市场成长。

市场趋势

目前，市场格局正因超速效吸入式胰岛素的出现而发生重塑。这种趋势优先考虑那些能够比传统皮下注射更精确地模拟健康胰臟生理胰岛素激增的製剂。这一趋势强调优化干粉製剂的动态粒径，以确保药物能够深层沉积于肺部并快速被全身吸收，从而降低餐后高血糖的风险。製造商正有效地将这种药物动力学优势转化为商业性成功，从而支撑了市场对速效、非侵入性替代疗法的需求。例如，Mankind公司在2024年11月发布的2024年第三季财报中宣布，Afrezza的净销售额已增至1500万美元，这表明吸入疗法呈现明显的增长态势，其增长动力来自不断增长的患者需求以及毛利润向净利润转化率的提高。

同时，口服和舌下胰岛素喷雾剂的创新也在加速发展。研究人员正在开发利用新型胜肽载体的技术，以穿透黏膜屏障，同时避免与胃肠道给药相关的降解问题。这一趋势的重点是开髮用于舌下给药的液体製剂，这种製剂可以透过丰富的血管网络直接进入血液，绕过肝臟的首过代谢，而肝臟首过代谢常常导致口服药物失效。这项技术进步直接满足了加拿大众多寻求无痛治疗方案的患者的需求。正如不列颠哥伦比亚大学在其2024年6月发表的报导《不列颠哥伦比亚大学开发的口服胰岛素滴剂为糖尿病患者带来福音》中所指出的那样，这些新型舌下滴剂是专门为帮助1170万加拿大糖尿病或糖尿病前期患者而设计的，凸显了此类粘膜给药创新在区域市场的巨大潜力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球非注射型胰岛素市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依产品类型（片剂、喷雾剂、其他）
    • 分销通路（医院药局、网路药局、药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美非注射用胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲非注射用胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区非注射胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲非注射胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲非注射胰岛素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球非注射胰岛素市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Midatech Pharma Plc
  • Shreya Life Sciences Pvt. Ltd.
  • Boston Therapeutics, Inc.
  • Coromed, Inc.
  • Diabetology Ltd.
  • Emisphere Technologies, Inc.
  • Oramed Pharmaceuticals, Inc.
  • Diasome Pharmaceuticals, Inc.
  • Generex Biotechnology Corp.
  • Biodel, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17079

The Global Non-Injectable Insulin Market is projected to expand from USD 3.69 Billion in 2025 to USD 6.46 Billion by 2031, registering a CAGR of 9.78%. This market sector focuses on alternative administration routes, including pulmonary inhalation and oral formulations, aimed at delivering insulin without invasive needles. The core catalyst for this growth is the increasing global prevalence of diabetes alongside the urgent necessity to enhance patient adherence among those experiencing needle phobia or injection fatigue. Data from the International Diabetes Federation indicates that approximately 589 million adults worldwide were living with diabetes in 2025, a vast patient population that drives significant demand for convenient therapeutic alternatives capable of overcoming the physical and psychological hurdles of traditional subcutaneous delivery.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.69 Billion
Market Size 2031USD 6.46 Billion
CAGR 2026-20319.78%
Fastest Growing SegmentDrug Stores
Largest MarketNorth America

Despite the evident benefits for patient quality of life, the market confronts a major obstacle regarding the reduced bioavailability of non-injectable forms compared to standard injectables. This physiological constraint typically requires higher dosage amounts to attain equivalent therapeutic results, which significantly elevates manufacturing expenses and the ultimate cost to the patient. Consequently, strict reimbursement frameworks and the substantial economic burden associated with these treatments serve as primary barriers that could hinder widespread clinical uptake and restrict market growth in regions sensitive to cost.

Market Driver

The primary factor driving the non-injectable insulin industry is the rising global incidence of diabetes mellitus, which intensifies the need to improve patient compliance among those burdened by the psychological and physical aspects of daily injections. This increasing disease prevalence demands scalable, user-friendly therapies that alleviate needle phobia. Projections from the International Diabetes Federation's 'IDF Diabetes Atlas 11th Edition' in 2025 estimate that the adult diabetic population will rise to roughly 853 million by 2050, emphasizing the critical need for alternative delivery systems. The magnitude of this demand is reflected in major pharmaceutical operations; for example, Novo Nordisk reported serving over 45.2 million individuals with serious chronic diseases in 2024, illustrating the massive scale of the patient base awaiting less invasive treatment methods.

Concurrently, the sector is being advanced by increased investment in research and development for alternative insulin formulations. Pharmaceutical companies are aggressively funding innovations in inhaled and oral delivery systems to surmount historical bioavailability issues and enhance therapeutic effectiveness. These financial commitments are essential for moving new technologies from clinical trials to commercial reality. A notable example occurred in February 2025, when Oramed Pharmaceuticals announced a strategic joint venture with a combined capital contribution of $75 million to expedite the development and commercialization of its oral insulin platform. Such significant capital injections confirm the industry's dedication to non-invasive solutions and are projected to fuel the next phase of market expansion by making pain-free insulin administration achievable.

Market Challenge

The principal impediment to the growth of the Global Non-Injectable Insulin Market is the physiological issue of lower bioavailability in pulmonary and oral formulations relative to standard injectables. Since these alternative delivery methods face difficulties in efficiently permeating biological barriers, manufacturers are required to formulate drugs with considerably larger amounts of active insulin to guarantee the patient receives the requisite therapeutic dose. This necessity for increased active pharmaceutical ingredients directly raises production costs, leading to a significantly higher end-price that restricts accessibility for both insurers and patients.

This price disparity creates a major obstacle in regions where healthcare budgets are already under severe strain. Rigid reimbursement policies frequently prioritize lower-cost traditional injectables, leaving costlier non-injectable options without sufficient coverage. The scale of this economic pressure is highlighted by recent statistics on the financial impact of the disease; according to the International Diabetes Federation, global health expenditure due to diabetes reached at least 1 trillion US dollars in 2025. Given these massive existing costs, payers remain hesitant to adopt premium-priced therapies, thereby limiting widespread clinical acceptance and impeding market growth in cost-sensitive areas.

Market Trends

The market is being reshaped by a focus on Ultra-Rapid Acting Inhaled Insulin, which prioritizes formulations that replicate the physiological insulin spike of a healthy pancreas more precisely than traditional subcutaneous injections. This trend emphasizes optimizing the aerodynamic particle size of dry powder formulations to guarantee deep lung deposition and rapid systemic absorption, thereby mitigating the risk of post-prandial hyperglycemia. Manufacturers are effectively converting this pharmacokinetic benefit into commercial success, confirming the demand for rapid-onset non-invasive alternatives. For instance, MannKind Corporation reported in its 'Third Quarter 2024 Financial Results' in November 2024 that Afrezza net revenue rose to $15.0 million, indicating a clear growth trajectory for inhaled therapeutics fueled by rising patient demand and better gross-to-net adjustments.

Concurrently, innovation in Buccal and Sublingual Insulin Sprays is gathering speed as researchers utilize novel peptide carriers to traverse the mucosal barrier without the degradation problems associated with gastrointestinal delivery. This trend focuses on creating liquid formulations administered under the tongue, where high vascularization permits direct entry into the bloodstream, bypassing the hepatic first-pass metabolism that frequently neutralizes oral medications. This technological advancement is directly meeting the needs of substantial national patient populations looking for pain-free options. As noted by the University of British Columbia in the June 2024 article 'UBC-developed oral insulin drops offer relief for diabetes patients,' these new sublingual drops are specifically designed to assist the 11.7 million Canadians living with diabetes or pre-diabetes, underscoring the vast regional market potential for such mucosal delivery innovations.

Key Market Players

  • Midatech Pharma Plc
  • Shreya Life Sciences Pvt. Ltd.
  • Boston Therapeutics, Inc.
  • Coromed, Inc.
  • Diabetology Ltd.
  • Emisphere Technologies, Inc.
  • Oramed Pharmaceuticals, Inc.
  • Diasome Pharmaceuticals, Inc.
  • Generex Biotechnology Corp.
  • Biodel, Inc.

Report Scope

In this report, the Global Non-Injectable Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Injectable Insulin Market, By Product

  • Pills
  • Sprays
  • and Others

Non-Injectable Insulin Market, By Distribution Channel

  • Hospital Pharmacies
  • and Online Pharmacies
  • Drug Stores

Non-Injectable Insulin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Injectable Insulin Market.

Available Customizations:

Global Non-Injectable Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Injectable Insulin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Pills, Sprays, and Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, and Online Pharmacies, Drug Stores)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Non-Injectable Insulin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Injectable Insulin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Non-Injectable Insulin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Non-Injectable Insulin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Distribution Channel

7. Europe Non-Injectable Insulin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Injectable Insulin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Non-Injectable Insulin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Non-Injectable Insulin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Non-Injectable Insulin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Non-Injectable Insulin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Non-Injectable Insulin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Injectable Insulin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Non-Injectable Insulin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Non-Injectable Insulin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Non-Injectable Insulin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Non-Injectable Insulin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Non-Injectable Insulin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Injectable Insulin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Non-Injectable Insulin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Non-Injectable Insulin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Distribution Channel

10. South America Non-Injectable Insulin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Injectable Insulin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Non-Injectable Insulin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Non-Injectable Insulin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Injectable Insulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Midatech Pharma Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Shreya Life Sciences Pvt. Ltd.
  • 15.3. Boston Therapeutics, Inc.
  • 15.4. Coromed, Inc.
  • 15.5. Diabetology Ltd.
  • 15.6. Emisphere Technologies, Inc.
  • 15.7. Oramed Pharmaceuticals, Inc.
  • 15.8. Diasome Pharmaceuticals, Inc.
  • 15.9. Generex Biotechnology Corp.
  • 15.10. Biodel, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer